What do systematic reviews say?

Slow passive expiration vs control

Slow passive expiration showed no clear difference in change in the severity status of bronchiolitis Assessed using a… compared with control (low certainty).

• Chest physiotherapy for acute bronchiolitis in paediatric patients between 0 and 24 months old 2023 · Cochrane Headline outcomes only
  no estimate extracted
  7 studies · 434 participants
  Low

Slow passive expiration vs control

• Chest physiotherapy for acute bronchiolitis in paediatric patients between 0 and 24 months old 2023 · Cochrane Headline outcomes only
  no estimate extracted
  6 studies · 565 participants
  Very low

Forced expiration vs control

• Chest physiotherapy for acute bronchiolitis in paediatric patients between 0 and 24 months old 2023 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 628 participants
  High

Forced expiration vs control

It is very uncertain whether forced expiration changes change in the severity status of bronchiolitis Assessed using a… compared with control (very low certainty).

• Chest physiotherapy for acute bronchiolitis in paediatric patients between 0 and 24 months old 2023 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 132 participants
  Very low

Forced expiration vs control

Forced expiration leads to higher adverse events ( compared with control (high certainty).

• Chest physiotherapy for acute bronchiolitis in paediatric patients between 0 and 24 months old 2023 · Cochrane Headline outcomes only
  RR 1
  2 studies · 599 participants
  High

Outpatient vs inpatients ‐ adults

Outpatients showed no clear difference in treatment failure compared with inpatients ‐ adults (moderate certainty).

• Outpatient treatment for people with cancer who develop a low‐risk febrile neutropaenic event 2019 · Cochrane Headline outcomes only
  RR 1.23 [0.82, 1.85]
  6 studies · 628 participants
  Moderate

Outpatient vs inpatients ‐ children

Outpatients showed no clear difference in adverse drug reactions compared with inpatients ‐ children (low certainty).

• Outpatient treatment for people with cancer who develop a low‐risk febrile neutropaenic event 2019 · Cochrane Headline outcomes only
  RR 1.9 [0.61, 5.98]
  2 studies · 156 participants
  Low

Outpatient vs inpatients ‐ children

• Outpatient treatment for people with cancer who develop a low‐risk febrile neutropaenic event 2019 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 119 participants
  Low

Outpatient vs inpatients ‐ children

• Outpatient treatment for people with cancer who develop a low‐risk febrile neutropaenic event 2019 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 305 participants
  Low

Outpatient vs inpatients ‐ adults

Outpatients showed no clear difference in mortality compared with inpatients ‐ adults (moderate certainty).

• Outpatient treatment for people with cancer who develop a low‐risk febrile neutropaenic event 2019 · Cochrane Headline outcomes only
  RR 1.04 [0.29, 3.71]
  6 studies · 628 participants
  Moderate

Outpatient vs inpatients ‐ adults

• Outpatient treatment for people with cancer who develop a low‐risk febrile neutropaenic event 2019 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 169 participants
  Low

Outpatient vs inpatients ‐ adults

Outpatients showed no clear difference in adverse drugs reactions compared with inpatients ‐ adults (low certainty).

• Outpatient treatment for people with cancer who develop a low‐risk febrile neutropaenic event 2019 · Cochrane Headline outcomes only
  RR 8.39 [0.38, 187.15]
  3 studies · 375 participants
  Low

Outpatient vs inpatients ‐ adults

• Outpatient treatment for people with cancer who develop a low‐risk febrile neutropaenic event 2019 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 251 participants
  Low

Outpatient vs inpatients ‐ children

Outpatients showed no clear difference in treatment failure compared with inpatients ‐ children (moderate certainty).

• Outpatient treatment for people with cancer who develop a low‐risk febrile neutropaenic event 2019 · Cochrane Headline outcomes only
  RR 1.04 [0.55, 1.99]
  4 studies · 366 participants
  Moderate

Outpatient vs inpatients ‐ children

Outpatients showed no clear difference in mortality compared with inpatients ‐ children (moderate certainty).

• Outpatient treatment for people with cancer who develop a low‐risk febrile neutropaenic event 2019 · Cochrane Headline outcomes only
  RR 0.63 [0.15, 2.7]
  3 studies · 329 participants
  Moderate

Outpatient vs inpatients ‐ children

• Outpatient treatment for people with cancer who develop a low‐risk febrile neutropaenic event 2019 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 305 participants
  Low

Prophylactic levosimendan vs usual care

Prophylactic levosimendan showed no clear difference in mortality compared with standard treatment (low certainty).

• Prophylactic levosimendan for the prevention of low cardiac output syndrome and mortality in paediatric patients… 2017 · Cochrane Headline outcomes only
  RR 0.47 [0.12, 1.82]
  3 studies · 123 participants
  Low

Prophylactic levosimendan vs usual care

Prophylactic levosimendan showed no clear difference in low cardiac output syndrome (LCOS) compared with standard treatment (low certainty).

• Prophylactic levosimendan for the prevention of low cardiac output syndrome and mortality in paediatric patients… 2017 · Cochrane Headline outcomes only
  RR 0.64 [0.39, 1.04]
  2 studies · 83 participants
  Low

Prophylactic levosimendan vs usual care

• Prophylactic levosimendan for the prevention of low cardiac output syndrome and mortality in paediatric patients… 2017 · Cochrane Headline outcomes only
  no estimate extracted
  4 studies · 188 participants
  Low

Prophylactic levosimendan vs usual care

• Prophylactic levosimendan for the prevention of low cardiac output syndrome and mortality in paediatric patients… 2017 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 75 participants
  Low